Michael Belkin (ophthalmologist)

Michael Belkin is an Israeli ophthalmologist known for his research and development work in the field of intraocular pressure (IOP) management and glaucoma. He is particularly recognized for his contributions to the development of the first ocular hypotensive drug derived from cannabinoids and for his innovative approaches to glaucoma treatment and prevention.

Belkin received his medical degree from the Hebrew University-Hadassah Medical School in Jerusalem. He then specialized in ophthalmology. Throughout his career, he has held various academic and research positions, including at Tel Aviv University.

Belkin's research has focused on the pathophysiology of glaucoma and the development of new pharmacological and surgical interventions. His work on cannabinoids and their potential to lower IOP led to significant advancements in glaucoma therapy. He has also been involved in developing novel devices and surgical techniques for managing glaucoma, aiming to improve patient outcomes and reduce vision loss.

Beyond his research, Belkin has been actively involved in teaching and mentoring ophthalmology residents and fellows. He has published numerous scientific articles in peer-reviewed journals and has presented his work at international conferences.

His contributions to ophthalmology have earned him recognition and awards within the field.